Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age

NCT07791186 is registered in ClinicalTrials.gov with BMI Korea as lead sponsor.

NCT NCT07791186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07791186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-center, Dose Escalation, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the BMI2012 Against COVID-19 Variant in Healthy Adults Between 19 and 55 Years of Age
Lead sponsor
BMI Korea
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2027
Enrollment
72 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of covid-19 variant (omicron jn.1)